The report covers 2023 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products
STUTTGART, Germany I March 08, 2024 I La Merie Publishing released the new report with sales data of recombinant biologics, biosimilars and novel biologic modalities. The report 2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation and analysis of the sales data of originator and biosimilar recombinant therapeutic proteins and antibodies in the calendar year 2023. In addition, information about sales data of novel biologics, i.e. gene & cell therapy and RNA, is presented.
For the first time, global sales of branded originator antibodies and proteins increased by 3.6% % to US$ 300.3 bln compared with the previous year. Excluding sales of SARS-CoV-2 antibodies in 2022, the growth rate would have been 6.8% (sales of SARS-CoV-2 antibodies decreased from US$ 8.9 bln in 2022 to US$ 0.8 bln in 2023). For comparison, global sales of biologics were US$ 63.8 bln in 2006 and US$ 112.9 bln in 2011. Since 2012, global sales of innovator biologics have grown with a continuous annual growth rate of 8.44%.
Antibody sales represented 83.6% of total biologics sales in 2023. The strong growth of antibody sales was mainly driven by novel anti-inflammatory antibodies and immuno-oncology antibodies. Sales of anti-inflammatory antibodies (including anti-TNF antibodies) exceeded those of cancer antibodies by US$ 25 bln despite the strong decrease of sales of anti-TNF antibodies (-23.6% vs 2022).
Blockbuster status with 2023 sales exceeding US$ 1 bln was achieved by 69 recombinant antibody and protein products, with seven new entrants (most notably Roche’s Vabysmo) and nine drop outs (SARS-CoV-2 antibodies and established proteins). Merck’s anti-PD-1 Keytruda is the new no. 1 blockbuster biologic as Humira sales decreased by 32.6% vs 2022. Roche retains its leadership position among the top 30 pharmaceutical company with the highest sales of biologics (US$ 41.2 bln).
The report presents and analyzes sales and growth rates of antibody-drug conjugates (ADC) and of bispecific antibodies and antibody combination (fixed dose or regimen). The report includes information of biosimilar sales as far as they have been published. The field is rather fragmented and consolidation is starting only slowly. Combined sales of novel biologic modalities for the first time have exceeded the threshold of US$ 10 bln (+27.6% vs 2022).
Methodology
The report covers sales data of more than 350 commercialized biologics with 50 new products included for the first time. Sales data were obtained from company publications and refer to innovative branded products as well as biosimilars and other biologics (gene & cell therapy, antisense, siRNA). All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of February 01, 2024. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates are presented as reported, except in some cases as constant exchange rates.
What you will find in the report:
Biologics Sales per Class of Branded Originator Products
- Sales of Established Therapeutic Proteins 2012 – 2023
- Sales and Growth Rates of Cancer Antibodies by Subgroup 2012 – 2023
- Sales and Growth Rates of Other Anti-Inflammatory Antibodies by Therapeutic Area 2012 – 2023
- Sales and Growth Rates of Antibody-Drug Conjugates by Product 2012 – 2023
- Sales and Growth Rates of Bispecific Antibodies & Combinations by Product 2015-2023
- Published Biosimilar Sales 2023 by Company
- Published 2023 Sales of Other Biologics Based on DNA, RNA & Cells
TOP 30 Company Ranking List for Sales of Innovator Biologics 2023
Blockbuster Biologics in 2023 (by generic name)
Individual Biologic Product Sales 2023:
1. Cancer Antibodies
2. Other Anti-Inflammatory Antibodies:
3. Anti-TNF Antibodies
4. Cardiometabolic Antibodies
5. Ophthalmic Antibodies
6. Insulin and Insulin Analogs
7. Recombinant Coagulation Factors
8. Enzyme Replacement Therapy (ERT)
9. Established Therapeutic Proteins:
10. Anti-Infective Antibodies
11. Migraine & Neurodegenerative Disease Antibodies
12. Other Proteins
13. Selected Biosimilar Antibodies & Proteins
14. Selected Other Biologics
The report 2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics can be acquired at La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2023-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 801
The report covers 2023 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products
STUTTGART, Germany I March 08, 2024 I La Merie Publishing released the new report with sales data of recombinant biologics, biosimilars and novel biologic modalities. The report 2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation and analysis of the sales data of originator and biosimilar recombinant therapeutic proteins and antibodies in the calendar year 2023. In addition, information about sales data of novel biologics, i.e. gene & cell therapy and RNA, is presented.
For the first time, global sales of branded originator antibodies and proteins increased by 3.6% % to US$ 300.3 bln compared with the previous year. Excluding sales of SARS-CoV-2 antibodies in 2022, the growth rate would have been 6.8% (sales of SARS-CoV-2 antibodies decreased from US$ 8.9 bln in 2022 to US$ 0.8 bln in 2023). For comparison, global sales of biologics were US$ 63.8 bln in 2006 and US$ 112.9 bln in 2011. Since 2012, global sales of innovator biologics have grown with a continuous annual growth rate of 8.44%.
Antibody sales represented 83.6% of total biologics sales in 2023. The strong growth of antibody sales was mainly driven by novel anti-inflammatory antibodies and immuno-oncology antibodies. Sales of anti-inflammatory antibodies (including anti-TNF antibodies) exceeded those of cancer antibodies by US$ 25 bln despite the strong decrease of sales of anti-TNF antibodies (-23.6% vs 2022).
Blockbuster status with 2023 sales exceeding US$ 1 bln was achieved by 69 recombinant antibody and protein products, with seven new entrants (most notably Roche’s Vabysmo) and nine drop outs (SARS-CoV-2 antibodies and established proteins). Merck’s anti-PD-1 Keytruda is the new no. 1 blockbuster biologic as Humira sales decreased by 32.6% vs 2022. Roche retains its leadership position among the top 30 pharmaceutical company with the highest sales of biologics (US$ 41.2 bln).
The report presents and analyzes sales and growth rates of antibody-drug conjugates (ADC) and of bispecific antibodies and antibody combination (fixed dose or regimen). The report includes information of biosimilar sales as far as they have been published. The field is rather fragmented and consolidation is starting only slowly. Combined sales of novel biologic modalities for the first time have exceeded the threshold of US$ 10 bln (+27.6% vs 2022).
Methodology
The report covers sales data of more than 350 commercialized biologics with 50 new products included for the first time. Sales data were obtained from company publications and refer to innovative branded products as well as biosimilars and other biologics (gene & cell therapy, antisense, siRNA). All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of February 01, 2024. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates are presented as reported, except in some cases as constant exchange rates.
What you will find in the report:
Biologics Sales per Class of Branded Originator Products
- Sales of Established Therapeutic Proteins 2012 – 2023
- Sales and Growth Rates of Cancer Antibodies by Subgroup 2012 – 2023
- Sales and Growth Rates of Other Anti-Inflammatory Antibodies by Therapeutic Area 2012 – 2023
- Sales and Growth Rates of Antibody-Drug Conjugates by Product 2012 – 2023
- Sales and Growth Rates of Bispecific Antibodies & Combinations by Product 2015-2023
- Published Biosimilar Sales 2023 by Company
- Published 2023 Sales of Other Biologics Based on DNA, RNA & Cells
TOP 30 Company Ranking List for Sales of Innovator Biologics 2023
Blockbuster Biologics in 2023 (by generic name)
Individual Biologic Product Sales 2023:
1. Cancer Antibodies
2. Other Anti-Inflammatory Antibodies:
3. Anti-TNF Antibodies
4. Cardiometabolic Antibodies
5. Ophthalmic Antibodies
6. Insulin and Insulin Analogs
7. Recombinant Coagulation Factors
8. Enzyme Replacement Therapy (ERT)
9. Established Therapeutic Proteins:
10. Anti-Infective Antibodies
11. Migraine & Neurodegenerative Disease Antibodies
12. Other Proteins
13. Selected Biosimilar Antibodies & Proteins
14. Selected Other Biologics
The report 2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics can be acquired at La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2023-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 801
